M&A Deal Summary |
|
|---|---|
| Date | 2015-10-29 |
| Target | Olink AB - Duolink |
| Sector | Life Science |
| Buyer(s) | Sigma-Aldrich |
| Sellers(s) | Olink |
| Deal Type | Divestiture |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1951 |
| Sector | Life Science |
| Employees | 9,800 |
| Revenue | 2.8B USD (2014) |
Sigma-Aldrich Corp. is a life science and high technology company whose biochemical, organic chemical products, kits, and services are used in scientific research, including genomic and proteomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical, diagnostics and high technology manufacturing. Sigma-Aldrich customers include more than 1.3 million scientists and technologists in life science companies, university, and government institutions, hospitals, and industry.
| DEAL STATS | # |
|---|---|
| Overall | 13 of 13 |
| Sector: Life Science M&A | 10 of 10 |
| Type: Divestiture M&A Deals | 3 of 3 |
| Country: Sweden M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-10-01 |
Pharmorphix
Cambridge, United Kingdom Pharmorphix Ltd. is a provider of solid form services, including polymorph studies, salt selection, co-crystallization, chiral separations and process scale up that are critical to successful drug discovery and development. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-15 |
Sigma-Aldrich Corp - Seelze
Germany Sigma-Aldrich - Seelze is a manufacturer of high-purity research chemicals and other materials used in new drug discovery, medical diagnostic testing and other laboratory applications. |
Sell | €105M |
| Category | Company |
|---|---|
| Founded | 2016 |
| Sector | Life Science |
| Employees | 667 |
| Revenue | 140M USD (2022) |
Olink provides leading solutions for advanced proteomics research and development, enabling biopharmaceutical companies and leading academic researchers to quickly and efficiently understand diseases at the protein level. Olink's proprietary technology, Proximity Extension Assay (PEA), enables high-throughput protein analysis for the very large installed base of qPCR and next-generation sequencing readout systems on the market. Olink was founded in 2016 and is based in Uppsala, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| Country: Sweden M&A | 1 of 1 |
| Year: 2015 M&A | 1 of 1 |
